Viking Therapeutics, Inc.
VKTX · XNASCIK 1607678fmd_1BE1NW0Q0R4Z26A51RZSCWV7Q9Manufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2014 to Sep 30, 2026, 51 periods
| Line item | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Realized investment gains (losses) | – | – | – | – | – | – | (0) | 0 | 0 | 0 |
| Research and development | 9 | 14 | 19 | 24 | 32 | 45 | 54 | 64 | 102 | 345 |
| Total operating expenses | 14 | 19 | 26 | 33 | 43 | 56 | 70 | 101 | 151 | 393 |
| Operating income | (14) | (19) | (26) | (33) | (43) | (56) | (70) | (101) | (151) | (393) |
| Other non-operating income (expense) | (1) | (2) | 4 | 7 | 3 | 1 | 1 | 15 | 41 | 34 |
| Income before taxes | – | – | – | – | – | – | – | (86) | (110) | (360) |
| Income tax expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net income from continuing operations | – | – | – | – | – | – | – | (86) | (110) | (360) |
| Net income | (15) | (21) | (22) | (26) | (39) | (55) | (69) | (86) | (110) | (360) |